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Yellow fever (YF) is an acute mosquito-transmit-
ted viral infection, endemic and occasionally
epidemic in many countries of Africa and South
America. Periodic outbreaks of yellow fever in East
Africa have been reported since 1940 (1,2) (Figure
1). The largest outbreak, an estimated 300,000 cases,
occurred from 1960 to 1962 in Ethiopia (3). In 1966,
YF reappeared in Arba-Minch, Ethiopia, east of Lake
Abaya, in an area not affected by the outbreak of
1960 to 1962. During the 1966 outbreak, 2,200 cases
(450 deaths) were reported (4). Despite the preva-
lence of anti-YF antibody in northern Kenya (up to
14%) (5,6), no outbreaks of YF were reported in
Kenya until 1992 when epidemic YF emerged in
Kenya for the first time, with at least 54 cases and
29 deaths (7). Cases of hemorrhagic fever were first
reported in September 1992, from the southern parts
of Keiyo (Kerio Valley), Baringo, and the Koibatek
Districts (former Elgeyo-Marakwet and Baringo dis-
tricts) in the Rift Valley Province, northwest Kenya
(Figure 2). Of the 54 patients with hemorrhagic fe-
ver, 35 (67%) were male. Of the 48 patients whose
definite age was known, 41 (85%) were 10 to 39 years
old. Twenty-one (39%) of the 54 patients had sero-
logic evidence of recent YF infection, and three of
the 21 had cases confirmed by isolation of YF virus.
The outbreak ended when the entire population of
these districts was vaccinated. A surveillance sys-
tem involving 13 sentinel sites was established 6
months after the epidemic was over. Six health fa-
cilities were located within the outbreak area of
Keiyo, Koibatek, and Baringo districts. Seven facili-
ties were situated in the surrounding areas of
Nakuru, Nyandarua, Kericho, and the Uasin Gishu
districts. In 1994, the number of sentinel sites was
increased to 18. Sentinel facilities were provided
with case investigation forms and equipment for
blood collection and storage. Surveillance activities
were ongoing, and supervisory visits were conducted
once every 6 weeks.
In Kenya, there are three levels of health care
delivery:  hospitals, health centers, and dispensa-
ries. In addition, missionary hospitals provide
independent health services.  Surveillance training
candidates were selected from district hospitals,
health centers, and mission hospitals. Training fo-
cused on case recognition, record keeping, use of a
YF case investigation form, handling of serum
samples, and obtaining exposure information. A field
guide for YF surveillance was developed in collabo-
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Figure 1. Yellow fever epidemics, East Africa.
ration with the World Health Organization (WHO)
and the Centers for Disease Control and Preven-
tion (CDC). A 1-day training workshop was followed
by a visit to the collaborating surveillance centers.
Medical staff at the health facility who could not
attend the workshop received on-the-job training.
A surveillance team consisted of a medical officer
(or scientist from the Virus Research Centre), a labo-
ratory technologist, the provincial public health
officer from Rift Valley Province, and a driver. In
October 1994, a second 1-day training workshop was
offered for five additional sentinel health facilities.
For surveillance purposes, a patient was considered
to have a case of YF if two of the following symptom
complexes were present: jaundice; hemorrhage;
signs of encephalitis or renal involvement; a tem-
perature > 38°C.
Serum was separated from blood samples on the
day of collection and stored frozen, until the serum
specimens could be transported by the surveillance
team.  Vaccine carriers with ice packs were used to
transport samples (along the surveillance route) to
the Kenya Medical Research Institute (KEMRI). In
1994, a liquid nitrogen container was added for
transporting samples. Samples were tested for YF
antibodies by the IgM-capture enzyme-linked
immunosorbent assay (MAC ELISA) (8) at the
Virus Research Centre. Selected acute-phase  sur-
veillance samples were also subjected to virus
isolation attempts, in which newborn mice and tis-
sue cultures were used. All serologic results were
confirmed by either CDC’s laboratory in Fort Collins,
Colorado, or the Institute Pasteur, Paris. Persons
whose illness met the surveillance case definition
were considered positive for recent YF infection ifVol. 2, No. 3—July-September 1996 Emerging Infectious Diseases
Dispatches
237
YF-specific IgM antibody was present in acute-phase
serum samples by MAC ELISA. Samples that were
borderline positive by IgM MAC ELISA were tested
for neutralizing antibody by the plaque reduction
neutralization test with YF virus. Results of this
sentinel surveillance from October 7, 1993, to De-
cember 31, 1995, are reported here.
One hundred-fifty persons, of whom 131 (87%)
had jaundice, met the surveillance case definition.
These were identified by 17 health facilities, during
a 27-month period (average, 5.5 per month; range,
0-12); 85 (57%) were male. Of the 138 persons whose
age was known, 117 (85%) were under 40 years of
age (average age, 21.4 years; range, 1 to 70 years).
Ten serologically confirmed cases were identified
by four health facilities.  All attempts to isolate the
virus were unsuccessful. The onset of the first con-
firmed case was March 1, 1994. The onset of the
latest case was May 15, 1995.  Seven confirmed cases
were from an area not known to be affected during
the 1992 to 1993 epidemic. The homes of six patients
border the districts where no YF vaccinations are
given (Figure 2). One patient (1994, Songhor, Nandi
District) lived far outside this area and had no his-
tory of travel to the known YF-endemic area. Five
patients with confirmed cases were male: eight
(80%) were under 40 years of age (average age, 26.5
years; range, 8 to 48 years).  All patients with con-
firmed cases had jaundice, and five (50%)
hemorrhaged from the nose or gums. Three patients
died (two were female). One was not vaccinated for
YF, and the vaccine status of two was unknown. The
case-fatality rate for patients with confirmed YF was
30%. All surviving patients had been vaccinated
(Table).
Timely reporting of disease emergencies is not
feasible through the existing health information sys-
tem in Kenya. When YF emerged there in September
1992, disease investigation was delayed, and the di-
agnosis was not confirmed until January 1993. In
the case of a limited health information system, sen-
tinel surveillance for YF, with active follow-up by
collaborating centers, seems appropriate for moni-
toring disease after an epidemic.
Most patients surveyed had fever and jaundice.
All patients with confirmed YF cases had jaundice,
and 50% hemorrhaged from the nose and gums.
Mild, nonspecific, and nonfatal clinical forms of yel-
low fever may have gone unnoticed as they did
during the 1992 to 1993 epidemic when YF virus
was isolated from a 12-year-old girl, who had fever,
headache and joint pains but no jaundice or signs of
hemorrhagic illness. (Outbreak of YF in Kenya,
1992-1993 Epidemiological Investigations, Sanders
et al., in preparation).
The continued low-level of transmission of YF
virus would likely have gone unnoticed if the en-
hanced surveillance and diagnostic capacity
instituted by the government of Kenya after the
1992-93 epidemic was not in place.  When cases of
YF were confirmed from an area not known to have
been affected during the outbreak, the Kenya Min-
istry of Health quickly recognized the problem and
resumed vaccinations (9,10).
Operational costs of the field visits to 18 senti-
nel sites are relatively high. Since nine (90%) of the
confirmed cases of YF were recognized by three hos-
pitals, which had cared for YF patients during the
previous epidemic, limiting the number of sentinel
Figure 2. Yellow fever surveillance in the Rift
Valley, Kenya.
Characteristics Number Percentage (%)
Sex, male 5 50
        female 5 50
Age, < 40 yeas 8 80
Jaundice 10 100
Hemorrhage 5 50
Deaths 3 30
History of YF vaccination        7a 70
aOnly non–fatal cases.
Table. Characteristics of patients with confirmed YF cases,
October 7, 1993, to December 31,1995Emerging Infectious Diseases Vol. 2, No. 3—July-September 1996
Dispatches
238
sites may be considered. Distributing materials to
obtain blood from persons with suspected cases does
not seem feasible countrywide.
The WHO initiative to create a global surveil-
lance program for recognition of and response to
emerging diseases emphasizes that a critical ele-
ment of surveillance includes a network of reference
centers that assist national services in disease di-
agnosis and investigation (11). In Kenya, the first
steps have been taken to establish such a reference
center at KEMRI in Nairobi. In 1994, two technolo-
gists were trained for an extensive period at CDC’s
laboratory in Fort Collins, Colorado, in the diagno-
sis of YF and other arboviral diseases. An
epidemiologic support unit was established at the
KEMRI laboratory to provide the link between pos-
sible disease occurrences in the field and the
diagnostic facilities at the distant laboratory.
Will this effort ensure that future epidemics will
be recognized? It is often argued that the critical
element of surveillance is disease recognition by
front-line health-care providers, subsequent inves-
tigation, sample collection, and the forwarding of
samples to available diagnostic facilities.  In Kenya
there is no focus on what diseases should be reported
immediately (monthly disease reporting at district
level requires health care workers to compile infor-
mation on 37 diseases). Communication between the
field and laboratory is often difficult. Once a speci-
men is forwarded, results often do not reach the
clinician who submitted the sample in a timely fash-
ion. Separate disease monitoring systems have been
initiated by different health programs, but they rely
on the same district officers to fill out the forms.
Admittedly, sentinel surveillance for YF has not been
integrated into one of the existing disease control
programs, and its sustainability as anything more
than a research program is questionable.
Hemorrhagic fever surveillance can be improved
by 1) arranging sentinel sites according to the pre-
sumed southward extension of the YF-endemic area,
2) managing supervision of the sentinel sites at pro-
vincial level, 3) integrating disease reporting for YF
in the surveillance system for EPI target diseases,
4) clearly defining which diseases need to be actively
monitored by health care providers, 5) instituting
improved diagnostic capabilities, and 6) forming a
disease outbreak team.
Transmission of YF poses a potential threat for
the largely unvaccinated population of Kenya and
other East African countries, especially since the YF-
endemic area appears to be expanding (12). YF
vaccination appears to be the only practical public
health intervention. Vaccination of children 6
months of age and older in the YF-endemic districts
(Keiyo, Marakwet, Baringo, and Koibatek) should
be continued. Districts adjacent to the disease-en-
demic area (Uasin Gishu, Kericho, Nandi, and
Nakuru) should be included in the vaccination pro-
gram.
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